What We Do
Epidemiological Surveillance of Psychotic Disorders
Due to the lack of national data on the prevalence of psychotic disorders in France, Santé publique France has, for the first time, estimated the prevalence of these disorders among children and adults, by sex and age, at both the national and regional levels.
To do so, Santé publique France analyzed data from the National Health Data System (SNDS). The SNDS, managed by the National Health Insurance Fund (Cnam), is a source of medical and administrative data covering approximately 99% of the French population. It contains:
Data on healthcare reimbursements (consultations and medical procedures, medications, laboratory tests, etc.). The history of these reimbursements is available for individuals enrolled in the general health insurance scheme since 2006, with data from other schemes being gradually integrated (the Agricultural Social Mutual Fund and the Social Scheme for the Self-Employed since 2009, and other specific schemes starting in 2012).
Data on hospitalizations in the public or private sector, in medicine-surgery-obstetrics (PMSI MCO), in psychiatry (RIM-P), in follow-up care and rehabilitation (PMSI SSR), and in home hospitalization (HAD). These data provide information on all medical diagnoses made during hospital stays, whether these diagnoses were coded as primary causes or associated causes. Data on SSR hospitalizations and home hospitalizations were not used to estimate the prevalence of psychotic disorders.
RIM-P data also provide information on outpatient follow-up at medical-psychological centers through the outpatient activity summary.
Data on care provided under ALD No. 23 “Long-term psychiatric conditions,” coded F20 to F29 in the ICD-10 for psychotic disorders or coded F20 for schizophrenia.
Medical causes of death (database of the Center for Epidemiology on Medical Causes of Death, CépiDC, of Inserm). These data were not used to estimate the prevalence of psychotic disorders.
See also
Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141.
McGrath J, Saha S, Welham J, El SO, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status, and methodology. BMC Med. 2004;2:13.
Krebs MO, Kebir O, Jay TM. Exposure to cannabinoids can lead to persistent cognitive and psychiatric disorders. Eur J Pain. 2019;23(7):1225-33.
The Health Status of the Population in France - 2017 Report (Drees).